Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,014 across all filing types
Latest filing 2017-03-30 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
第三届监事会第十二次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of a company regarding multiple reports and proposals related to the fiscal year 2016, including the Supervisory Board Work Report, Financial Statements, Audit Report, Annual Report, Internal Control Evaluation Report, Profit Distribution Plan, Fundraising Usage Report, and appointment of the audit firm for 2017. The document contains voting results and states that these reports will be submitted to the 2016 Annual General Meeting for approval. The document itself does not contain the full reports but announces the resolutions and approvals of these reports by the Supervisory Board. The document length is 2534 characters, which is relatively short and consistent with an announcement rather than the full reports. Therefore, according to the MENU VS MEAL RULE, this document is an announcement of resolutions and approvals related to the Annual Report and other reports, not the reports themselves. Hence, the appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit other specific categories and is not the full Annual Report or Audit Report itself.
2017-03-30 Chinese
2016年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the "2016 Annual Report Summary" of 福安药业（集团）股份有限公司, indicating it is a summary of the full annual report. It contains detailed financial data for the year 2016, including revenue, net profit, quarterly financial data, shareholder information, and dividend distribution plans. The presence of audited financial statements and comprehensive business descriptions aligns with the characteristics of an Annual Report. The document is about 15,000 characters long, which is substantial and contains actual financial data, not just an announcement or a certification. Therefore, it is classified as an Annual Report (10-K). FY 2016
2017-03-30 Chinese
国都证券股份有限公司关于公司发行股份及支付现金购买资产暨关联交易之2016年度持续督导核查意见暨持续督导总结报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2016年度持续督导核查意见暨持续督导总结报告" which translates to "2016 Annual Continuous Supervision and Verification Opinion and Summary Report" by an independent financial advisor regarding a share issuance and cash purchase of assets and related party transactions by 福安药业 (Fuan Pharmaceutical Group). It includes detailed verification of asset transfer, capital verification, share registration, fulfillment of commitments, profit forecast realization, business development status, and corporate governance structure. The document is a detailed supervisory report on a major asset restructuring transaction, including financial and operational analysis for the year 2016. It is not a full annual report (10-K), nor a simple announcement or certification. It is a standalone audit/supervisory report related to a specific transaction and its ongoing compliance and performance, fitting the category of Audit Report / Information (AR). The document length is 4462 characters, which is sufficient for a substantive report rather than a brief announcement. Therefore, the classification is AR with high confidence. FY 2016
2017-03-30 Chinese
东莞证券股份有限公司关于公司发行股份及支付现金购买资产并募集配套资金之2016年年度持续督导工作报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2016 Annual Continuous Supervision Work Report" by an independent financial advisor (Dongguan Securities) regarding a transaction involving the issuance of shares and cash payment to purchase assets and raise supporting funds by Fu'an Pharmaceutical (Group) Co., Ltd. The content includes detailed descriptions of the transaction, asset transfer, share issuance, fulfillment of commitments, performance forecasts, management discussion and analysis, and corporate governance structure. It is a comprehensive report on the ongoing supervision of a major asset restructuring transaction, including financial and operational details, performance commitments, and governance compliance. The document is not a full annual report of the company, nor is it a simple announcement or certification. It is a specialized report related to a capital transaction and ongoing supervision thereof. This type of document fits best under the category of Capital/Financing Update (CAP), as it provides detailed updates on the company's fundraising, financing activities, and capital structure changes related to the issuance of shares and cash payment for asset acquisition and fundraising.
2017-03-30 Chinese
2016年度财务决算报告
Annual Report Classification · 100% confidence The document is titled as the "2016 年度财务决算报告" which translates to "2016 Annual Financial Settlement Report". It contains detailed financial data including income, profit, cash flow, assets, liabilities, and notes explaining changes in financial statement items. The report is audited by an accounting firm with an unqualified opinion, indicating it is a formal financial report. The length is over 5,000 characters and contains comprehensive financial statements and analysis for the full fiscal year 2016. This matches the definition of an Annual Report (10-K) which covers company activity and full financial performance for the year. There is no indication that this is merely an announcement or a certification, nor is it a quarterly or interim report. Therefore, the document should be classified as an Annual Report (10-K). FY 2016
2017-03-30 Chinese
关于烟台只楚药业有限公司2016年度业绩承诺实现情况的说明
Regulatory Filings Classification · 95% confidence The document is a detailed explanation regarding the performance commitment achievement of Yantai Zhichu Pharmaceutical Co., Ltd. for the year 2016, related to a major asset restructuring transaction by Fuan Pharmaceutical (Group) Co., Ltd. It includes information about the asset acquisition, share issuance, compensation agreements, and audited financial results for 2016. The document references regulatory rules from the China Securities Regulatory Commission and includes an audit report number, but it is not itself an audit report or a full annual report. It is a specific disclosure about the performance commitment related to a major asset restructuring, which is a regulatory disclosure often filed as a Regulatory Filing (RNS) in the context of Chinese listed companies. The document length is under 5,000 characters, and it is a detailed explanation rather than a simple announcement. It does not fit the definitions of Annual Report, Audit Report, or Capital/Financing Update. Therefore, the best classification is Regulatory Filings (RNS).
2017-03-30 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.